SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-016646
Filing Date
2023-05-09
Accepted
2023-05-09 09:00:39
Documents
69
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q espr-20230331.htm   iXBRL 10-Q 1193268
2 EX-31.1 espr-ex311x03312023.htm EX-31.1 11023
3 EX-31.2 espr-ex312x03312023.htm EX-31.2 11092
4 EX-32.1 espr-ex321x03312023.htm EX-32.1 8378
  Complete submission text file 0001628280-23-016646.txt   6647052

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20230331.xsd EX-101.SCH 59228
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT espr-20230331_cal.xml EX-101.CAL 47630
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT espr-20230331_def.xml EX-101.DEF 291986
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20230331_lab.xml EX-101.LAB 651488
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20230331_pre.xml EX-101.PRE 436371
63 EXTRACTED XBRL INSTANCE DOCUMENT espr-20230331_htm.xml XML 980078
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35986 | Film No.: 23900199
SIC: 2834 Pharmaceutical Preparations